Table 2—

Summary of pharmacokinetic and glucodynamic results by subject group and treatment

Healthy
Mild asthma
Moderate asthma
AIRSubcutaneous lisproAIRSubcutaneous lisproAIRSubcutaneous lisproAIR + salbutamol
Pharmacokinetic
    NPK*25132611221211
    AUC0-t′ (nmol · min/l)35.2 (46.1)61.1 (25.4)24.0 (59.5)65.2 (26.6)21.1 (74.8)59.5 (17.1)31.3 (36.8)
    Cmax (pmol/l)248 (46.0)421 (38.7)185 (41.3)432 (36.8)183 (29.0)374 (35.8)221 (27.0)
    tmax (min)50 (11–131)48 (34–64)51 (12–124)62 (32–125)48 (12–124)62 (32–191)60 (22–121)
Glucodynamic
    NGD*25122510181110
    Gtot (g)38.7 (108.0)59.7 (43.6)23.4 (156.0)73.5 (33.2)10.7 (159.0)47.8 (88.5)15.5 (180.0)
    Rmax (mg/min)355 (59.5)471 (30.8)290 (70.1)526 (41.8)183 (68.3)401 (56.1)261 (69.5)
    tRmax (min)47 (33–174)79 (44–130)47 (26–104)67 (25–153)52 (3–132)81 (46–184)62 (34–110)
  • Data are geometric means (coefficients of variation) (%); median (range) are shown for tmax and tRmax. Cmax, maximum serum insulin concentration; GD, glucodynamics; Gtot, total amount of glucose infused throughout the clamp; NGD, number of GD observations; NPK, number of PK observations; PK, pharmacokinetics; Rmax, maximum glucose infusion rate; tmax, time to maximum insulin concentration; tRmax, time to maximum glucose infusion rate.

  • *

    * Differences in number of observations between NPK and NGD by group for a given parameter are due to incomplete (due to either discontinuations or noncomputable data) or outlying data.